**Name of Journal:** World Journal of Gastroenterology

**Manuscript NO:** 76116

**Manuscript Type:** ORIGINAL ARTICLE

**Observational Study**

International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis

International patterns of pancreatic cancer.

**Abstract**

**BACKGROUND**

Pancreatic cancer, as the one of most fatal malignancies, remains a critical issue in global burden of disease.

**AIM**

The aim of this manuscript was to estimate trends in pancreatic cancer incidence and mortality worldwide in last three decades.

**METHODS**

A descriptive epidemiological study was done. Pancreatic cancer incidence and mortality data were obtained from the database of the World Health Organization. Analysis of pancreatic cancer incidence and mortality during 2020 was performed. The age-standardized rates (ASRs, expressed per 100,000) were presented. To estimate trends of incidence and mortality of pancreatic cancer, joinpoint regression analysis was used: the average annual percent change (AAPC) with the corresponding 95% confidence interval (95%CI) was calculated. Additionally, analysis was performed by sex and age. In this paper, the trend analysis included only countries with high and medium data quality.
RESULTS
A total of 495,773 (262,865 males and 232,908 females) new cases and 466,003 (246,840 males and 219,163 females) deaths of pancreatic cancer were reported worldwide in 2020. In both sexes, most of the new cases (191,348; 38.6% of the total) and deaths (182,074; 39.1% of the total) occurred in the Western Pacific Region. In both sexes, the highest ASRs were found in the European Region, while the lowest rates were reported in the South-East Asia Region. The general pattern of rising pancreatic cancer incidence and mortality was seen across countries worldwide in observed period. Out of all countries with an increase in pancreatic cancer incidence, females in France and India showed the most marked rise in incidence rates (AAPC=+3.9% and AAPC=+3.7%, respectively). Decreasing incidence trends for pancreatic cancer were observed in some countries, but without statistical significance. Out of all countries with an increase in pancreatic cancer mortality rates, Turkmenistan showed the most marked rise both in males (AAPC=+10.0%, 95%CI=7.4-12.5) and females (AAPC=+6.4%, 95%CI=3.5-9.5). The mortality trends of pancreatic cancer were decreasing in both sexes only in Canada and Mexico.

CONCLUSION
Further research is needed to explain the cause of large international differences in incidence and mortality trends of pancreatic cancer in last three decades.

Key Words: Pancreatic cancer; Incidence; Mortality; Joinpoint analysis.

Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis. World J Gastroenterol 2022; In press
Core Tip: Pancreatic cancer, as one of the most fatal malignancies, remains a critical issue in global burden of disease. About 500,000 new cases and 470,000 deaths of pancreatic cancer were recorded in 2020 across the world. Globally, the rate of pancreatic cancer incidence in 2020 was 4.9 per 100,000 for both sexes together, while mortality rate was 4.5 per 100,000. Increasing trends in both incidence and mortality of pancreatic cancer were observed in most countries across the world. Further efforts to explore the reasons for differences in international pattern in pancreatic cancer incidence and mortality could be critical for global cancer control.

INTRODUCTION
Pancreatic cancer is one of the most lethal cancers, with insidious onset, extremely aggressive nature and poor prognosis[1-3]. The 5-year overall survival rate of pancreatic cancer is low (approximately 10%), since more than half of the cases are confirmed at an advanced stage[3,4]. Based on GLOBOCAN 2020 estimates, pancreatic cancer remains a large part of global burden of disease, and ranks as the 12th most common malignancy (2.6% of all cancers) and the 7th leading cause of cancer mortality (4.7% of all cancers)[1,2]. Age-standardized incidence and mortality rates are about 5-fold higher in countries with high/very high Human Development Index than in low/medium countries[2].

World Health Organization (WHO) estimated pancreatic cancer as the 3rd leading cancer-related cause of death in people of all ages for both sexes in the United States of America, Germany, Italy, Austria, Czechia, Finland, Hungary, Malta, Spain and Switzerland in 2020[2]. In four countries (Finland, Qatar, Benin, and France Guadeloupe), pancreatic cancer was the 2nd leading cause of death of all cancers in 2020 in females aged 70 years and over[2]. The Global Burden of Disease (GBD) Study ranked pancreatic cancer as the 7th top cause of absolute Years of Life Lost (YLLs) among all cancers in both sexes in 2017, while it ranked 9th in 2007 among the top causes for YLLs worldwide[5]. Also, GBD study showed that the Disability Adjusted Life Years (DALYs) caused by pancreatic cancer have more than doubled from 1990 to 2017 globally[6].
The age patterns were similar for both incidence and mortality of pancreatic cancer, with the rates increasing with increasing age; the burden moderately grew after 30 years of age and came to peak after 80 years of age, with similar trend in males and females\cite{3,5-7}. In 27 countries of the European Union (EU) and in the United Kingdom, between 1990 and 2019, incidence and mortality from pancreatic cancer significantly increased by 0.65\% and 0.55\% per year, respectively\cite{8}.

WHO and the United Nations Sustainable Development Goals (UNSDGs), published in 2015, target to reduce premature mortality rate attributed to cancer by one third by 2030\cite{9}. However, according to Ferlay et al.\cite{10}, by 2025 there will be more deaths annually from pancreatic cancer in the EU countries than deaths from breast cancer and it will become the third most important cause of cancer death in the EU after lung and colorectal cancer. In addition, a particularly important issue is how the COVID-19 pandemic will affect the management of patients with pancreatic cancer that can be disrupted or delayed, particularly in the context of treatment selection and postoperative care to reduce the risk of SARS-CoV-2 associated morbidity and mortality\cite{11,12}.

Recent estimates suggest that pancreatic cancer is becoming a critical public health challenge and a growing health service issue both in developed and developing countries\cite{1,10,13}. The aim of this manuscript was to assess international patterns in incidence and mortality of pancreatic cancer.

**MATERIALS AND METHODS**

*Study design*

This descriptive epidemiological study comprised the annual underlying cause of disease and death data to describe trends in incidence and mortality from pancreatic cancer in the world in last three decades.

*Data source*
Data of pancreatic cancer incidence and mortality were extracted from the WHO databases[2], *i.e.* the GLOBOCAN estimates of cancer incidence and mortality generated by the International Agency for Research on Cancer. Pancreatic cancer estimates included site code C25, based on the 10th revision of the International Classification of Diseases and Related Health Problems to classify cause of disease and death (ICD-10)[14].

The WHO databases provide a comprehensive and comparable assessment of incidence and mortality of pancreatic cancer[2]. These databases provide high-quality statistics based on national vital registries worldwide. The methods used to compile the GLOBOCAN 2020 estimates involved predictions, modeling of incidence-to-mortality ratios, and approximation from neighboring countries. For pancreatic cancer, we extracted all incidence and mortality data available from WHO databases in all calendar years available since 1991. The WHO estimates comprise only national mortality data series that meet the minimal inclusion criteria according to the WHO-defined medium data quality level, based on degree of population coverage, completeness and accuracy[15]. Level of data quality was classified using criteria described by WHO[14]: data of high quality (ICD-9 or ICD-10 coding is used and completeness is > 90% and ill-defined codes appear on < 10% of registrations), medium quality (completeness is 70–90% OR ill-defined codes appear on 10–20% of registrations OR non-ICD codes used although completeness is > 90% and ill-defined codes appear on < 10% of registrations) and low quality (completeness < 70% OR ill-defined codes appear on > 20% of registrations).

This manuscript presents the incidence and mortality figures for 185 WHO Member States, as well as for six WHO regions (Africa, Americas, South-East Asia, Europe, Eastern Mediterranean, and Western Pacific). First analysis of incidence and mortality for pancreatic cancer shown in the manuscript regards the year 2020. The trends analyses included only countries with data of pancreatic cancer incidence/mortality available in the observed period (from 1991 or later) continuously, provided that there has been data for at least 15 years in a row continuously. Countries with
“missing” values in any year of trend analysis were excluded from the analysis. Specifics about the availability of incidence and mortality data of pancreatic cancer since 1991, as well as the quality classification of data for different countries by years in observed period are defined in Supplementary Table 1. In this paper, the trend analysis included only countries with high / medium data quality.

For pancreatic cancer incidence and mortality, all figures were adjusted by age and presented as age-standardized rates (ASRs, per 100,000 persons) calculated by the direct method of standardization by age and sex, using the World standard population according to the Segi-Doll World reference population\[2\].

**Statistical analysis**

Trends in pancreatic cancer incidence and mortality rates were calculated using Joinpoint regression analysis software (Joinpoint Version 4.9.0.0; National Cancer Institute, Bethesda, Maryland, USA – March 2021, available through the Surveillance Research Program of the US National Cancer Institute), proposed by Kim et al\[16\]. The joinpoint regression analysis was used to assess the magnitude and direction of temporal trends in incidence and mortality of pancreatic cancer. The joinpoint regression analysis detected point(s), the so-called “joinpoint(s)”, at which there was a significant change in trend in rates of pancreatic cancer, using the calendar year as a regression variable. The age-standardized rate was used as the dependent variable, while the by-variables were sex and age group. A Monte Carlo permutation test for multiple comparisons was used and 4499 randomly selected data sets, which finds “the best fit” line for each segment\[16\]. The analysis starts with a minimum of zero joinpoints (i.e. a straight line) and tests whether a change in the trend was statistically significant by testing more joinpoints up to the maximum of four joinpoints (five segments)\[16\]. The resulting regression equation is: \( y = a + bx \), where \( y = ln(rate) \) and \( x = \) calendar year, with slope \( a \) and \( y \)-intercept \( b \), whereby Average Annual Percent Change (AAPC) is estimated as \( 100 \times (eb - 1) \). Grid Search method was selected\[17\]. In this manuscript, trend of pancreatic cancer incidence and mortality of each country was presented with a
straight line in the whole period, even if there were changes in trends in the observed period. The AAPC over the entire considered period with the corresponding 95% confidence interval (95%CI) was determined \[16\]. In describing the direction of temporal trends, the terms “significant increase” or “significant decrease” were used, in order to signify that the slope of the trend was statistically significant (p < 0.05, on the basis of the statistical significance of the AAPC compared to zero). Additionally, analysis was performed by sex and age (30-49, 50-69, 70+) in selected countries. Trends were not evaluated separately among persons aged under 30 years due to the very small numbers of pancreatic cancer cases in this age group. A line diagram of joinpoint analysis for individual countries provides information about the number of the joinpoints for the trends in incidence and mortality of pancreatic cancer by sex, by describing of Annual Percent Change (APC) and the corresponding 95%CI.

**Ethics statement**

This study was approved by the Ethics Committee of the Faculty of Medical Sciences, University of Kragujevac (No. 01-14321).

**RESULTS**

**Pancreatic cancer incidence and mortality: year 2020 results**

Globally, the total number of new pancreatic cancer cases was 495,773 in 2020: it was diagnosed in 262,865 (53%) males and 232,908 (47%) females (Figure 1). The total number of pancreatic cancer deaths was 466,003 (246,840 males and 219,163 females). Male to female ratio was: 1.1:1 both for incidence and mortality. In both sexes, most new cases (191,348; 38.6% of the total) and deaths (182,074; 39.1% of the total) occurred in the Western Pacific Region. In males, the least number of pancreatic cancer new cases (6062; 2.3% of total) and deaths (5920; 2.4% of total) was recorded in the African region. In females, the least number of pancreatic cancer new cases (5048; 2.2% of total) and deaths (4924; 2.2% of total) was recorded in the Eastern Mediterranean region.
The global ASR of incidence of pancreatic cancer was 4.9 per 100,000 population in both sexes (5.7 in males vs. 4.1 in females), and ASR of mortality was 4.5 (5.3 in males vs. 3.8 in females) (Figure 2). In both sexes, the highest incidence ASRs were found in the European Region (9.3 in males vs. 6.2 in females), while the lowest rates were reported in the South-East Asia Region (1.6 in males vs. 1.0 in females). Also in both sexes, the highest mortality ASRs were found in the European Region (8.7 in males vs. 5.7 in females), while the lowest rates were reported in the South-East Asia Region (1.6 in males vs. 1.0 in females).

There were significant international variations in incidence and mortality of pancreatic cancer in 2020 (Figures 3 and 4). The highest ASRs of incidence and mortality of pancreatic cancer in both sexes in 2020 were reported in Hungary (11.2 and 10.2, respectively). The highest incidence ASRs in males and females were found in Hungary (13.7 and 9.2 per 100,000), followed by Uruguay (12.8 and 8.9), while the lowest rates (equally about 0.5) were reported in Botswana, Eswatini and Malawi in males and in India, Sri Lanka and Pakistan in females. The highest mortality ASR in males was found in Hungary (12.6) and in females in Uruguay (8.5), while the lowest rate was reported in Malawi in males (0.46) and in Pakistan in females (0.30). In comparison to males, the incidence and mortality ASRs were lower in females in countries across the world in 2020: the only exception was for females in Bahrain, Belize, Brunei, Burkina Faso, Cabo Verde, Eswatini, Gabon, Ghana, Kenya, Libya, Malawi, Nepal, New Zealand, Peru, Qatar, Gambia, Uganda and United Arab Emirates in whom rates higher than in men were recorded.

**Patterns in pancreatic cancer incidence trends**

Most of the countries showed a meaningful increase in pancreatic cancer incidence in both males and females, but the magnitude of increasing incidence trends for pancreatic cancer was higher in females than in males in almost all countries (Figure 5). Out of all countries with an increase in pancreatic cancer incidence, females in France and India showed the most marked rise in incidence rates (AAPC=+3.9% and AAPC=+3.7%, respectively). In males in Kuwait and Turkey the most marked rise in incidence rates
was recorded (in both equally by AAPC=+3.6%). In some countries, pancreatic cancer incidence trends were significantly increasing in females (in Czechia, Germany, India, Latvia, Lithuania, Malta, Netherlands, Norway, and Switzerland), in contrast to males. Decreasing trends of pancreatic cancer incidence were observed in some countries but without statistical significance. In some of the most developed countries (such as the United Kingdom, Sweden) in both sexes a significantly increasing trends in pancreatic cancer incidence rates were observed in the last decade, which followed a previous period characterized by a declining incidence trend (Supplementary Figure 1). In contrast to that, after 2 decades of continuous growth, a downward trend of pancreatic cancer incidence rates in both sexes happened in the more recent decade in Denmark.

**Pattern in pancreatic cancer mortality trends**

The majority of analyzed countries showed a significant increase in pancreatic cancer mortality in both males and females, but the magnitude of mortality increasing trends for pancreatic cancer was higher in females than in males in almost all countries since 1991 (Figure 6). Out of all countries with an increase in pancreatic cancer mortality rates, Turkmenistan showed the most marked rise both in males (AAPC=+10.0%, 95%CI=7.4-12.5) and females (AAPC=+6.4%, 95%CI=3.5-9.5). In some countries, pancreatic cancer mortality trends were significantly increasing in males (in Colombia, Kyrgyzstan and Mauritius), in contrast to females. The results of our study suggest that there are only 2 countries where significant decreasing pancreatic cancer mortality trends were observed in both sexes: Canada (by -0.4% per year in males and by -0.2% per year in females) and Mexico (by -0.7% in males and -0.8% in females). However, there are only 2 countries where decreasing pancreatic cancer mortality trends were observed in males only: Czechia (by -0.4% per year) and Ireland (by -0.7%). In some of the most developed countries (such as the United States of America, the United Kingdom, Germany) a significantly increasing trends in pancreatic cancer mortality rates were observed since the 1990s (Supplementary Figure 2).

**Pattern in pancreatic cancer trends according to age classes, by sexes**
The greatest increase in pancreatic cancer incidence was noted in aged 70+ in France in both males (by +4.2% per year) and females (by +4.9%) (Table 1). An increase was observed in most of the countries in both sexes for persons aged 50 and above. A decreasing trend in incidence of pancreatic cancer was recorded only in females aged 70 and above in Canada (by -0.3% per year). Also, a decreasing trend in pancreatic cancer incidence in males aged 70 and above was noted only in Canada (by -0.4% per year). In males aged 30-49, incidence rates decreased mainly in transitional countries (Czechia by -1.9%, Estonia -2.1%, Latvia -2.2%, Lithuania -2.2%, Slovakia -1.5%). In almost all countries a significantly increasing trend in mortality of pancreatic cancer was recorded both in males and females aged 70 and above. A similar pattern was observed in aged 50-69. The greatest increase in pancreatic cancer mortality was in aged 70+ in Turkmenistan in both males (by +12.8%) and females (by +11.4%). Large disparities were observed in changes of rates among the young age group, where mortality rates decreased over the study period for most countries. The favorable change was higher in transitional countries (Czechia by -3.3% in males, -2.7% in females; Latvia by -2.7% in males, -4.7% in females).

**DISCUSSION**

In 2020, the highest incidence and mortality rates of pancreatic cancer were reported in developed countries. The pattern of rising pancreatic cancer incidence and mortality was seen across countries worldwide in the last three decades, in both developed and transitioned populations. Increasing trend was most pronounced among persons aged 50 years or older, similarly among males and females. However, it is promising that pancreatic cancer mortality rates were declining in some countries such as Canada and Mexico.

In both sexes together, the highest incidence and mortality rates of pancreatic cancer in 2020 were reported in the European region (7.6 cases and 7.1 deaths per 100,000 persons, respectively) and the Americas region (6.2 cases and 5.4 deaths per 100,000 persons, respectively), while the lowest were recorded in South-East Asia.
(equally 1.3 cases and deaths per 100,000 persons). Since due to delayed disease detection and limited effectiveness of therapies the survival for pancreatic cancer remains very poor\textsuperscript{[3,4,19]}, its mortality is still largely determined on its incidence. Besides, the overall survival rates vary very little between developed and developing countries\textsuperscript{[20]}. Since the risk of pancreatic cancer occurrence increases linearly with age and the average age at the time of diagnosis of pancreatic cancer is 70\textsuperscript{[2-6]}, significant geographic differences in pancreatic cancer incidence and mortality rates could be explained by differences in life expectancy at birth by region: although improving continuously in all regions in the past decades, life expectancy at birth in 2019 was the highest in countries in Northern America and Europe, and the lowest in South Asia and Africa\textsuperscript{[21]}. Also, the Global Burden of Disease study showed the association of age-standardized incidence and mortality rates for pancreatic cancer with development status at the national level (measured by the Socio-demographic Index, that composes the total fertility rate among women under the age of 25, mean education for individuals aged 15 and older, and income per capita) in 2017\textsuperscript{[6]}. Based on the current evidence, international variations in incidence rates of pancreatic cancer are mainly attributed to exposure to environmental factors, particularly tobacco smoking, obesity, diabetes mellitus, alcohol consumption\textsuperscript{[6,22,23]}. Additionally, the migrant effect among Japanese in Hawaii\textsuperscript{[24]} and the discrepancies in pancreatic cancer incidence in Chinese populations\textsuperscript{[25]}, which share a similar genetics, but have lived in different regions, indicate that cancer development was mainly determined by environmental factors. Based on the WHO 2015 estimates, the prevalence of tobacco smoking was the highest in countries in the European region (35\% in Greece, equally 33\% in the Russian Federation and Serbia), intermediate (about 20\%) in Western Pacific and Eastern Mediterranean, and the lowest (nearly 10\%) in Africa and Americas\textsuperscript{[26]}. Based on the results of the Global Burden of Disease Study, pancreatic cancer deaths worldwide were primarily attributable to smoking (25.9\% in males, 16.1\% in females), high fasting plasma glucose (9.3\% in males, 8.6\% in females), and high body-mass index (5.0\% in males, 7.4\% in females) in 2017\textsuperscript{[6]}. In both sexes together in 2017, fraction of pancreatic
cancer age-standardized deaths attributable to smoking was the highest in central Europe (28.2% of all pancreatic cancer deaths), while the highest fraction attributable to high fasting plasma glucose was observed in Oceania (16.6%), and the highest fraction attributable to high body mass index was observed in high-income North America (10.2%)\textsuperscript{61}. Similarly, the correlation analysis of risk factors for pancreatic cancer for 48 countries showed that higher incidence and mortality rates among men were significantly associated with higher prevalence of smoking, alcohol drinking, physical inactivity, obesity and high cholesterol levels\textsuperscript{27}. At the same time, pancreatic cancer rates among women were linked with higher prevalence of smoking, alcohol drinking and high cholesterol. On the other hand, the correlation analysis indicated absence of association between the prevalence of diabetes mellitus and the incidence and mortality for pancreatic cancer. Contrary, a recent meta-analysis involving 23 cohort studies indicated that diabetes mellitus was associated with a 52% excess risk for pancreatic cancer\textsuperscript{28}. However, the issue of the validity of a cancer certificate always exists and the impact of variations in data quality on incidence rate cannot be ruled out, especially for pancreatic and other cancers with poorer prognosis and in older age groups\textsuperscript{29,30}. Pancreatic cancer incidence rates in the world in 2020 indicate the possibility that there is an underestimation of the incidence rates in many countries, mainly in developing countries\textsuperscript{21}. Namely, many countries reported the incidence rate that was equal to the mortality rate of pancreatic cancer in 2020, while in few countries the mortality rate was higher than the incidence rate\textsuperscript{22}. Besides, in many countries cancer registries were not populational, but sometimes reported data only from urban / metropolitan area.

Our study showed unfavorable trends in pancreatic cancer incidence rates in both males and females in many countries in the world in the last three decades. The incidence was noticeably increasing throughout European countries, the United States of America, Australia, and Japan, while stable trends in incidence were noted in Canada, Sweden and Ireland. One previous study showed that pancreatic cancer incidence rates gradually increased in males and females among all ages in the USA,
Canada, the Netherlands, Australia, New Zealand from the mid-1990 until 2014\textsuperscript{31}. In the same study, a decreasing trend of pancreatic cancer incidence in males was noticed only in Iceland and Croatia, while in women there was a significant increasing trend in the incidence of pancreatic cancer in most of the countries from the 1990s onwards\textsuperscript{31}. The pancreatic cancer incidence in both sexes in China increased continuously from 1990 to 2019\textsuperscript{32}. The observed increasing trends in pancreatic cancer incidence could be attributed to population growth and ageing, as well as changes in the prevalence of risk factors for cancer\textsuperscript{6,33,34}. Global Burden of Disease study demonstrated that there was a link between increasing trends in incidence for pancreatic cancer and increases in development status at the national level in period 1990-2017\textsuperscript{8}. Also, one previous study indicated that increasing trends in pancreatic cancer incidence in both sexes were correlated with socioeconomic development (measured by Human Development Index and Gross Domestic Product per capita)\textsuperscript{35}. In the 1980s, a rapid social and economic transition from the lifestyle that characterized socialistic countries (such as countries of the former Eastern Bloc, etc) to an industrialized westernized lifestyle took place\textsuperscript{36-38}; it is hypothesized that, with a lag phase, undergoing different states of social and economic transition has contributed to the sharply increasing trends of pancreatic cancer incidence that have been observed in east and south European countries, China, Brazil since 2000s. Based the results of the Czech MONICA and post-MONICA studies, cigarette smoking prevalence declined significantly only in males (from 45.0\% in 1985 to 23.9\% in 2016/17), while there was no change in the prevalence of smoking in females (from 20.9\% to 25.9\%) over the analyzed period\textsuperscript{38}. Throughout the entire 30-year survey period, for both sexes significantly decreased prevalence of dyslipidemia and the consumption of meat and fat was observed, with increase in vegetable oils intake and fresh fruit and vegetable, whereas a significant increase in body mass index was observed in males only\textsuperscript{38}. Both the incidence and mortality trends of pancreatic cancer significantly increased in China during the last decades, which could be due to the rise of the prevalence of overweight to 28.1\%, diabetes to 11.2\%, and smoking to 28.1\% of adults: namely, China consumes about 40\% of the world's total cigarettes, and that
predominantly among men, with a large increase in consumption over the past decades. A large-scale nationwide cohort study in the Republic of Korea, which included 9,514,171 adults during a median follow-up period of 7.3 years, indicated that diabetes and alcohol use were associated with an increased risk of pancreatic cancer. On the other hand, the influence of the improvement of medical imaging on the diagnosis of pancreatic cancer, that is, on the increasing trends of the incidence of pancreatic cancer during the last decades cannot be ruled out.

Pancreatic cancer mortality rates across the countries showed an increasing trend in both sexes. A decreasing trend, on the other hand, was found in both sexes only in Canada and Mexico, and a level-off was observed in Denmark, Norway, Sweden, Panama, Republic of Moldova, and Venezuela. With the exception of some developing countries (Latvia, Kyrgyzstan, Mauritius, Turkmenistan, Nicaragua and Colombia), in all other populations the magnitude of the increase in mortality from pancreatic cancer was higher in women. While the increased trends of pancreatic cancer mortality have long been observed in developed countries (such as the United States of America, Japan, Germany, France, Italy, Spain), in recent years a precipitous increase has also been reported in developing countries (such as Kyrgyzstan, Turkmenistan, Bulgaria, Serbia, etc). Some of these changes have been associated with western lifestyle and environmental factors which are linked to an increased risk of pancreatic cancer occurrence (including smoking, diabetes, alcohol consumption, obesity, physical inactivity, high-energy food intake, etc). International patterns in incidence and mortality trends of pancreatic cancer in the last three decades mostly reflect different phases of the smoking epidemic across countries, and among males and females. In support of that, our study indicated that mortality rates from pancreatic cancer showed a slower rise among women and a drop among men in China in the last decade (from 1998 to 2012), which could be affected by reduced prevalence of tobacco consumption. Also, significantly decreasing trends in pancreatic cancer mortality in both sexes in Mexico (especially since 2008) can partially be attributed to changes in
smoking patterns which are resulting from new tobacco tax/Laws which were implemented in Mexico in 2007/2008\textsuperscript{[46]}. Unfortunately, due to the silent nature of disease, late diagnosis, and limited treatment options, and the metastatic potential of pancreatic cancer cells, and its poor prognosis, most pancreatic cancers are diagnosed at an advanced stage, which is not amenable to treatment\textsuperscript{[42,43]}. Differences in the international patterns in incidence and mortality trends of pancreatic cancer in the last three decades could be pertinent to impel continuous efforts to identify novel risk factors (particularly the modifiable risk factors) and implement policies for more effective pancreatic cancer control\textsuperscript{[34]}. Global inequalities in standard medical practices (prevention/diagnosis/therapy) and their impact on pancreatic cancer mortality have not yet been systematically explored\textsuperscript{[47]}.

In our study, significantly less favorable pancreatic cancer incidence trends in the young age group (30-49 years) were observed in women compared to men in all countries. Both older age groups (50-69 and 70+ years), for both men and women, generally showed similar trends in the incidence of pancreatic cancer. Other studies have reported similar results\textsuperscript{[29,30]}. Similar to incidence, significantly less favorable trends in mortality of pancreatic cancer in the young age group (30-49 years) were observed in women compared to men in all countries. In both older age groups (50-69 and 70+ years), both men and women generally showed similarly increasing trends in the mortality of pancreatic cancer. It is particularly promising that in males in young age group (30-49 years) pancreatic cancer mortality trends were falling in most of the countries. Some studies also reported an increasing trend in mortality for pancreatic cancer in the past decade, especially among women and those 50 years or older in some countries\textsuperscript{[24,28]}. Although in countries where there is a significant trend of increasing incidence of pancreatic cancer, this increase was recorded at the age of 50 and older, of particular concern is the significant trend of increasing incidence of pancreatic cancer in the youngest group (30-49 years), which is registered in our study mainly in developed countries (United Kingdom, USA, Australia, France, Israel, Italy, and Bulgaria). Also, although the trend of increasing mortality from pancreatic cancer was recorded at the
age of 50 and above, the significant trend of increasing mortality from pancreatic cancer among the youngest group (30 to 49 years) in women is particularly worrying (mainly in developed countries such as the USA, France, Germany, Spain, and Brazil) and in males in Chile, China, Brazil and El Salvador. Although there is no unified definition, some authors defined the onset of pancreatic cancer at an age of 50 or younger as early-onset pancreatic cancer\textsuperscript{38,49}. Similar to our results, one study found a significantly increasing trend in incidence of pancreatic cancer among persons younger than 40 years only in women in 4 high-income countries (Canada, the United Kingdom, France and the Netherlands)\textsuperscript{27}. Despite the fact that some studies suggest an association with cigarette smoking, genetic factors, obesity and metabolic disorders, the reasons for the increasing trends in incidence and mortality of early-onset pancreatic cancer are still not well understood\textsuperscript{50-52}. Population data on tobacco use from 12 European countries revealed that in both men and women, smoking prevalence was the highest among young adults aged 25–44 years, and decreased with increasing age\textsuperscript{50}. Results of 2 prospective US cohort studies indicated that established risk factors were more strongly associated with earlier-onset pancreatic cancer (ie among those aged ≤60 years), while association attenuated among elderly\textsuperscript{51}. The question of whether the frequency of performing diagnostic and therapeutic procedures, as well as autopsies at a younger age has an impact on the trend in incidence and mortality from earlier-onset pancreatic cancer should also be clarified in future research\textsuperscript{53}.

However, certain comparisons of trends may not be feasible due to the unavailability or incompleteness of data in the registries from some countries. Additionally, some factors may contribute to difficulties in international comparisons, including differences in quality of data (such as variations in medical certification, the coding process, accuracy, coverage and completeness of death certification, frequency and registry of autopsies)\textsuperscript{3}. But, and besides that, the observed disparities in trends for pancreatic cancer incidence and mortality across the countries can help generate
hypotheses of pancreatic cancer etiology, enable the identification of unknown risk factors, as well as to evaluate preventive/therapy measures. Therefore, the assessment of the patterns in trends in incidence and mortality for pancreatic cancer in the world based on available data from registries that did not cover all countries (primarily without all African countries and many Asian countries) is difficult, does not allow for accurate interpretation or valid generalization.

Along with either increasing or stable current incidence and mortality trends of pancreatic cancer in many countries, with the aging population and the increase in prevalence of certain risk factors (cigarette smoking, overweight/obesity, diabetes, alcohol use), and taking into consideration that screening for pancreatic cancer is currently not recommended, it would be difficult to expect that the UN-SDG's goal of reducing mortality from cancers (hence pancreatic cancer) by one-third by 2030 can be achieved[8]. Additionally, pancreatic cancer survival is still consistently low[20]. Since the COVID-19 pandemic began there has been concern regarding the possible delay in the diagnosis/treatment of pancreatic cancer patients, as indicated by a recent study in Portugal[54] about the pancreatic cancer having been diagnosed at a later stage during the pandemic, which is a matter that should be elucidated in future research. In summary, the marked international differences in rates and trends in incidence and mortality of pancreatic cancer indicate the need for introducing a more effective public health approach to prevention and improvements in diagnostic and treatment practices worldwide.

**Strengths and limitations**

This study analyzed both incidence and mortality figures of pancreatic cancer for 185 WHO member states for 2020. Also, our study analyzed international patterns in trends of incidence and mortality of pancreatic cancer in the last three decades by sex and by age groups. One of the major strengths of our study is the use of the GLOBOCAN database, the large population-based datasets, whereby the trends analysis was conducted only for countries with quality of data that was classified as high or medium quality level. Finally, the described international patterns and trends in pancreatic
cancer incidence and mortality over time may be useful in generating hypotheses about risk factors for pancreatic cancer. However, several possible sources of limitations in this study should be considered. First, there is always a question of reliability and validity of cancer certificates. Also, the quality of data varies significantly from country to country. Additionally, comparison between some countries could be difficult because statistical data quality might change and differ over time. Further, an issue of under-reporting of pancreatic cancer, particularly in developing countries, could introduce bias in the assessment of incidence and mortality trends. Availability of data for the incidence/mortality of pancreatic cancer for each country is different, in some countries very limited. Not all of the data are available for all of the years in the analyzed period (since 1991). Therefore, the data of incidence and mortality are taken for different intervals for some countries, which makes it much more difficult to compare trends across countries. Besides, our trend analysis did not cover countries with statistical data classified as low quality data, which therefore did not allow comparisons for a number of countries. In addition, for some countries, data on pancreatic cancer were available either for incidence only or for mortality only, so greater caution in the inference about trends is recommended. Finally, an epidemiological fallacy is an inherent limitation of this study. Possible modes of mitigation for the above mentioned limitations include greater diagnostic accuracy of pancreatic cancer, better quality of death certification, implementation of mandatory population-based cancer registry, further reduction of the proportion of uncertain causes of death, introduction of registration of autopsies (eg part of pancreatic cancer cases diagnosed at autopsy was missing on the death certificates), provision of survival data for pancreatic cancer patients, as well as the improvements and availability of pancreatic cancer treatment across countries. Based on accurate assessment of epidemiological characteristics of pancreatic cancer, policymakers could provide a better planning for funding, access to more effective treatment and care strategies, scientific and clinical advances in development of effective screening tests, improving early diagnosis and improving survival. Despite these limitations, this
study can help assess the international patterns in incidence and mortality trends of pancreatic cancer, which still need to be elucidated in analytical epidemiological studies in the future.

CONCLUSION
Increasing trends in pancreatic cancer incidence and mortality were observed in last three decades in numerous countries, in both sexes and most age groups. Further efforts to explore the reasons of differences in international pattern of pancreatic cancer incidence and mortality could be critical for global disease control.

ARTICLE HIGHLIGHTS
Research background
Pancreatic cancer, as the one of most fatal malignancies, remains a critical issue in global burden of disease.

Research motivation
The main motivation of this study is to describe the international patterns in incidence and mortality trends of pancreatic cancer in last three decades. Accurate assessment of pancreatic cancer burden is crucial for a more effective disease control.

Research objectives
The aim of this manuscript was to estimate trends in incidence and mortality due to pancreatic cancer in the world in last three decades.

Research methods
A descriptive epidemiological study was done. Pancreatic cancer incidence and mortality data were obtained from the WHO database. The age-standardized rates (ASRs, expressed per 100,000) were presented. To estimate trends of incidence and mortality of pancreatic cancer, joinpoint regression analysis was used: the average
annual percent change (AAPC) with the corresponding 95% confidence interval (95%CI) was calculated.

Research results
The general pattern of rising pancreatic cancer incidence and mortality was seen across countries worldwide in observed period. Out of all countries with an increase in pancreatic cancer incidence, females in France and India showed the most marked rise in incidence rates (AAPC=+3.9% and AAPC=+3.7%, respectively). Decreasing pancreatic cancer incidence trends have been observed in some countries but without statistical significance. Out of all countries with an increase in pancreatic cancer mortality rates, Turkmenistan showed the most marked rise both in males (AAPC=+10.0%, 95%CI=7.4-12.5) and females (AAPC=+6.4%, 95%CI=3.5-9.5). The mortality trends of pancreatic cancer were decreasing in both sexes only in Canada and Mexico.

Research conclusions
The increasing trends in incidence and mortality from pancreatic cancer were observed across the world, particularly in developed countries. The favorable pattern in trends in incidence and mortality of pancreatic cancer was reported in only a few countries.

Research perspectives
Further research is needed to explain the cause of large international differences in incidence and mortality trends of pancreatic cancer.
<table>
<thead>
<tr>
<th>Primary Source</th>
<th>Title and Details</th>
</tr>
</thead>
</table>
   Internet | 134 words — 2% |
| 2 | www.pancreaticcancereurope.eu  
   Internet | 37 words — 1% |
| 3 | Junjie Huang, Veeleah Lok, Chun Ho Ngai, Lin Zhang et al.  
   "Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer", Gastroenterology, 2021 | 34 words — 1% |
| 4 | Cezary Wojtyla, Paola Bertuccio, Andrzej Wojtyla, Carlo La Vecchia.  
   "European trends in breast cancer mortality, 1980–2017 and predictions to 2025",
   European Journal of Cancer, 2021 | 27 words — < 1% |
   "Disparities of birth cohort effects on pancreatic cancer incidence between the United States and urban China", ESMO Open, 2021 | 25 words — < 1% |
| 6 | Mariana Brito, Ana Laranjo, Júlia Sabino, Carla Oliveira, Irina Mocanu, Jorge Fonseca.  
   "Digestive Oncology in the COVID-19 Pandemic Era", GE - Portuguese Journal of Gastroenterology, 2021 | 19 words — < 1% |
<table>
<thead>
<tr>
<th></th>
<th>Source</th>
<th>Words</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>wp.cov19longhaulfoundation.org</td>
<td>18</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>8</td>
<td>journals.plos.org</td>
<td>17</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>9</td>
<td>web.era-edta.org</td>
<td>17</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>10</td>
<td><a href="http://www.jstage.jst.go.jp">www.jstage.jst.go.jp</a></td>
<td>14</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>12</td>
<td><a href="http://www.csir.co.za">www.csir.co.za</a></td>
<td>13</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>14</td>
<td><a href="http://www.pubfacts.com">www.pubfacts.com</a></td>
<td>12</td>
<td>&lt; 1%</td>
</tr>
</tbody>
</table>